

Smart4Fabry Final Workshop

Wednesday, 3rd February 2021

For any problem, please contact:
Catalina Martínez Carazo
Mobile phone: +34 616 014 587
catalina.martinez@keralty.com

Online venue:

Further relevant information regarding the event will be provided on <https://smart4fabry.eu/>

Facilitator: Nathaly Segovia (CIBER/ICMAB-CSIC). Smart4Fabry project manager.

- 14:00 - 14:15** **Introduction to the clinical problem: Lysosomal Storage Disorders (LSDs)-Fabry:** Guillem Pintos Morell (Vall d'Hebron Research Institute).
- 14:15 - 14:25** **Smart4Fabry project: A European joint effort to use nanotechnology in Enzymatic Replacement Therapy development:** Nora Ventosa (CIBER/ICMAB-CSIC). Coordinator of the project.
- 14:25 - 14:45** **Optimizing the nanoformulation: a long trip from lab to reality**
- Formulation CQA. Elisabet González (CIBER/ICMAB-CSIC).
 - Targeting peptides. Miriam Royo (CIBER/IQAC-CSIC).
- 14:45 - 15:25** **Does it look nice? Advanced approaches to nanodrugs characterization**
- Dganit Danino. (Technion- Israel Institute of Technology).
 - Characterization of the nanoformulation structure and multi-lamellarity by SAXS. Jan Skov Pedersen (Aarhus University).
- 15:25 - 15:35** **Production Optimization and Scale up-How to not get lost in translation:** Alba Córdoba (Nanomol Technologies).
- 15:35 - 15:45** **Making nanomedicines safe: Safety by design:** Andreas Falk (BioNanoNet Forschungsgesellschaft mbH (BNN)).
- 15:45 – 16:05** *Break*
- 16:05 - 16:15** **The right vehicle, but what about the passenger? - GLA development:** José Luis Corchero (CIBER/UAB) & Andreu Soldevila (Leanbiopro).
- 16:15 - 16:35** **Is it working properly: *In vitro* and *in vivo* evaluation**
- In vitro and in vivo efficacy of GLA nanoliposomes. Ibane Abasolo (CIBER/ Vall d'Hebron Research Institute).
 - Nonclinical safety evaluation. Hazel Clay (Covance).
- 16:35 - 16:45** **Barriers to be crossed: Challenges on evaluating BBB crossing:** Thomas Birngruber (Joanneum Research).
- 16:45 - 17:15** **Round table. Making the most of our results: Open innovation, exploitation and business development:** Ángel del Pozo (Biokeralty), Andreu Soldevila (Leanbiopro), Santi Sala (Nanomol Technologies) - Andreas Falk (BioNanoNet Forschungsgesellschaft mbH (BNN)).